FTC's PBM Case Paused For More Deal Talks
By Matthew Perlman · February 12, 2026, 7:15 PM EST
Federal Trade Commission staffers are discussing potential settlements with OptumRx and Caremark that could end the agency's case accusing the pharmacy benefit managers of inflating insulin prices, following a recent deal...
To view the full article, register now.